Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 12/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207128 | 0.89 | CAMK2D (0.50) | CAMK2DKCNH2 | |
| SCHEMBL20186428 | 0.79 | CAMKK1 (0.45) | CAMKK1CAMKK2CAMK2DPIK3CDCYBB | |
| SCHEMBL20186323 | 0.79 | CAMKK1 (0.45) | CAMKK1CAMKK2CAMK2DPIK3CDCYBB | |
| SCHEMBL20186107 | 0.74 | CAMKK1 (0.47) | CAMKK1CAMKK2CAMK2DPIK3CDKCNH2 | |
| SCHEMBL20186103 | 0.74 | CAMKK1 (0.47) | CAMKK1CAMKK2CAMK2DPIK3CDKCNH2 | |
| SCHEMBL20186087 | 0.73 | CAMKK1 (0.50) | CAMKK1CAMKK2CAMK2DPIK3CD | |
| SCHEMBL20186125 | 0.73 | CAMKK1 (0.48) | CAMKK1CAMKK2CAMK2DPIK3CDKCNH2 | |
| SCHEMBL20186086 | 0.73 | CAMKK1 (0.50) | CAMKK1CAMKK2CAMK2DPIK3CD | |
| SCHEMBL20186122 | 0.73 | CAMKK1 (0.48) | CAMKK1CAMKK2CAMK2DPIK3CDKCNH2 | |
| SCHEMBL20186261 | 0.72 | CAMKK1 (0.48) | CAMKK1CAMKK2CAMK2DPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | CAMKK1 2/4885CAMKK2 8/4885CAMK2D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.